Amedisys (AMED) Tops Q3 EPS by 96c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amedisys Reports Third Quarter 2020 Financial Results - Updates 2020 Guidance
October 28, 2020 4:05 PM EDTBATON ROUGE, La., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2020.
Three-Month Periods Ended September 30, 2020 and 2019
Net service revenue increased $49.5Â million to $544.1Â million compared to $494.6Â million in 2019.Net income attributable to Amedisys, Inc. of $72.0Â million compared to $34.1Â million in 2019.Net income attributable to Amedisys, Inc. per diluted share of $2.16 (inclusive of $0.72 income tax benefit related to executive stock option exercise) compared to $1.03 in 2019.Adjusted Quarterly Results*
Adjusted EBITDA of $75.7Â million compared to $56.8Â million in... More